Exocrine pancreatic cancer remains as one of the deadliest cancers. Conventional treatments have little impact on disease outcome. Molecular research on both sporadic and inherited forms of pancreatic cancer, has yielded important advances in the understanding of the disease at the molecular level. The availability of in vitro and in vivo models allows the design of pathophysiologic studies in this tumour. As a consequence, new molecular therapeutic targets have been identified. Gene therapy, antiangiogenic treatments, immunotherapy, and signal-transduction inhibition are in preclinical development. This review presents an update of molecular biology aspects and their potential applications in the daily clinical practice. Copyright © 2005 Aran Ediciones, S. L.
|Original language||American English|
|Number of pages||15|
|Journal||Revisiones en Cancer|
|State||Published - 29 Jul 2005|